Biomarkers of AML
The following table shows some of the biomarkers of AML resourced from the published literatures.
Click here to download the table :
Note: All biomarkers listed in the table are linked to their respective gene expression and methylation data. For microRNAs, there's no expression or methylation information available.
Biomarker | Biomolecule | Subject | Regulation | Type | Experiment | Significance | Source | PubMedID | Methods | Tools | Cohort | Profiling |
---|---|---|---|---|---|---|---|---|---|---|---|---|
HCK | mRNA | Human | Upregulation | Prognostic | Stromal, immune, and ESTIMATE scores evaluation | p<0.048 | TCGA-LAML | 35280440 | Pathway Enrichment Analysis, Protein-Protein Interaction (PPI) Network, Cox Regression Analysis and Kaplan-Meier Survival Analysis, Gene Set Enrichment Analysis , Go Analysis, Kegg Analysis | ESTIMATE and CIBERSORT algorithms, R package, clusterprofiler package, STRING database, Cytoscape, Spearman’s or Pearson’s correlation test, heatmap, intersection analysis | 200 patients | Expression, Methylation |
ITGB2 | mRNA | Human | Upregulation | Prognostic | Stromal, immune, and ESTIMATE scores evaluation | p<0.005 | TCGA-LAML | 35280440 | Pathway Enrichment Analysis, Protein-Protein Interaction (PPI) Network, Cox Regression Analysis and Kaplan-Meier Survival Analysis, Gene Set Enrichment Analysis , Go Analysis, Kegg Analysis | ESTIMATE and CIBERSORT algorithms, R package, clusterprofiler package, STRING database, Cytoscape, Spearman’s or Pearson’s correlation test, heatmap, intersection analysis | 201 patients | Expression, Methylation |
ITGAM | mRNA | Human | Upregulation | Prognostic | Stromal, immune, and ESTIMATE scores evaluation | p<0.04 | TCGA-LAML | 35280440 | Pathway Enrichment Analysis, Protein-Protein Interaction (PPI) Network, Cox Regression Analysis and Kaplan-Meier Survival Analysis, Gene Set Enrichment Analysis , Go Analysis, Kegg Analysis | ESTIMATE and CIBERSORT algorithms, R package, clusterprofiler package, STRING database, Cytoscape, Spearman’s or Pearson’s correlation test, heatmap, intersection analysis | 202 patients | Expression, Methylation |
CCR5 | mRNA | Human | Upregulation | Prognostic | Stromal, immune, and ESTIMATE scores evaluation | p<0.021 | TCGA-LAML | 35280440 | Pathway Enrichment Analysis, Protein-Protein Interaction (PPI) Network, Cox Regression Analysis and Kaplan-Meier Survival Analysis, Gene Set Enrichment Analysis , Go Analysis, Kegg Analysis | ESTIMATE and CIBERSORT algorithms, R package, clusterprofiler package, STRING database, Cytoscape, Spearman’s or Pearson’s correlation test, heatmap, intersection analysis | 203 patients | Expression, Methylation |
CD4 | mRNA | Human | Upregulation | Prognostic | Stromal, immune, and ESTIMATE scores evaluation | p<0.003 | TCGA-LAML | 35280440 | Pathway Enrichment Analysis, Protein-Protein Interaction (PPI) Network, Cox Regression Analysis and Kaplan-Meier Survival Analysis, Gene Set Enrichment Analysis , Go Analysis, Kegg Analysis | ESTIMATE and CIBERSORT algorithms, R package, clusterprofiler package, STRING database, Cytoscape, Spearman’s or Pearson’s correlation test, heatmap, intersection analysis | 204 patients | Expression, Methylation |
CSF1R | RNA | Human | Downregulation | Prognostic | Platelet-decreased AML Vs platelet-not decreased AML | p<0.05 | TCGA, GDAC | 35887121 | Differentially Expressed Gene Analysis, Pathway Analysis and Network Analysis, Kolmogorov–Smirnov and Shapiro–ilk Test,wilcoxon Rank Sum Test ,chi-square For Trend Or Fisher’s Exact Test | Support Vector Machines, Random Forest, logistic regression, Leave-One-Out Cross-Validation, DESeq2 , ROCR, factoextra R package,gplots, Cytoscape software | 37 NK-AML patients. | Expression, Methylation |
TNFSF15 | RNA | Human | Downregulation | Prognostic | Platelet-decreased AML Vs platelet-not decreased AML | p<0.05 | TCGA, GDAC | 35887121 | Differentially Expressed Gene Analysis, Pathway Analysis, And Network Analysis, Kolmogorov–Smirnov and Shapiro–Wilk Test, Wilcoxon Rank Sum Test , Chi-Square For Trend Or Fisher’s Exact Test | Support Vector Machines, Random Forest, logistic regression, Leave-One-Out Cross-Validation, DESeq2 , ROCR, factoextra R package,gplots, Cytoscape software | 38 NK-AML patients. | Expression, Methylation |
CLEC10A | RNA | Human | Downregulation | Prognostic | Platelet-decreased AML Vs platelet-not decreased AML | p<0.05 | TCGA, GDAC | 35887121 | Differentially Expressed Gene Analysis, Pathway Analysis, And Network Analysis, Kolmogorov–Smirnov and Shapiro–Wilk Test, Wilcoxon Rank Sum Test , Chi-Square For Trend Or Fisher’s Exact Test | Support Vector Machines, Random Forest, logistic regression, Leave-One-Out Cross-Validation, DESeq2 , ROCR, factoextra R package,gplots, Cytoscape software | 39 NK-AML patients. | Expression, Methylation |
Basigin(BSG) | RNA | Human | Upregulation | Prognostic and Diagnostic | AML cell lines (Kasumi-3,Kasumi-1, NB4, HT93, MUTZ-3, and U937)vs normal CD34+ cells | p<0.05 | Cell Line | 35054026 | RNA extraction, Gene Expression Analysis, ELISA , Western Blot ,DNA isolation, SNP selection and genotyping | Real Statistics Resource Pack for Microsoft Excel 2013, RStudio ,GraphPad Prism , Haploview 4.2 software, Fisher’s exact test | 37 AML patients and 25 healthy blood donors for serum BSG,92 AML patients and 135 healthy blood donors BSG and MCT1 genetic variants analysis | Expression, Methylation |
MCTs | RNA | Human | Upregulation except mutz-3 | Prognostic | AML cell lines (Kasumi-3,Kasumi-1, NB4, HT93, MUTZ-3, and U937)vs normal CD34+ cells | p<0.05 | Cell Line | 35054026 | RNA extraction, Gene Expression Analysis, ELISA , Western Blot ,DNA isolation, SNP selection and genotyping | Real Statistics Resource Pack for Microsoft Excel 2013, RStudio ,GraphPad Prism , Haploview 4.2 software, Fisher’s exact test | 38 AML patients and 25 healthy blood donors for serum BSG,92 AML patients and 135 healthy blood donors BSG and MCT1 genetic variants analysis | Expression, Methylation |
CLL-1 | protein | Human | Downregulation | Prognostic and Diagnostic | comparing CLL-1 with CD33 and CD34 | p<0.05 | Bone Marrow | 33778076 | Chisquare Test, Student’s t test, Kaplan-Meier method, Log-rank tests. Univariate and Multivariate analysis, Cox-Regression model | SPSS 19 software | 52 patients | Expression, Methylation |
FLT3 | mRNA | Human | Upregulation | Prognostic and Predictive | mRNA chip datasets comparison between AML patients and normal BM tissues | p<0.05 | GEPIA2,TCGA and GEO ,blood | 35116245 | Functional Enrichment Analysis, Protein-Protein Interaction (PPI) Network, Survival analysis, Spearman Correlation Analysis | STRING (11.0) database and Cytoscape (3.7.2) software, GSCA Lite, Molecular Complex Detection, Centralities for Cytoscape (Centiscape2.2),Gene Ontology,KEGG) pathway enrichment, BloodSpot, Cancer Therapeutics Response Portal (CTRP) analysis,DAVID,Genomics of Drug Sensitivity in Cancer (GDSC) | GSE947626 samples of AML patients and 20 samples of healthy volunteers, while GSE30029 contained 90 samples of AML patients and 31 samples of healthy volunteers | Expression, Methylation |
PF4 | mRNA | Human | Upregulation | Prognostic and Predictive | mRNA chip datasets comparison between AML patients and normal BM tissues | p<0.05 | GEPIA2,TCGA and GEO ,blood | 35116245 | Functional Enrichment Analysis, Protein-Protein Interaction (PPI) Network, Survival analysis, Spearman Correlation Analysis | STRING (11.0) database and Cytoscape (3.7.2) software, GSCA Lite, Molecular Complex Detection, Centralities for Cytoscape (Centiscape2.2),Gene Ontology,KEGG) pathway enrichment, BloodSpot, Cancer Therapeutics Response Portal (CTRP) analysis,DAVID,Genomics of Drug Sensitivity in Cancer (GDSC) | GSE947626 samples of AML patients and 20 samples of healthy volunteers, while GSE30029 contained 90 samples of AML patients and 31 samples of healthy volunteers | Expression, Methylation |
CD163 | mRNA | Human | Upregulation | Prognostic and Predictive | mRNA chip datasets comparison between AML patients and normal BM tissues | p<0.05 | GEPIA2,TCGA and GEO ,blood | 35116245 | Functional Enrichment Analysis, Protein-Protein Interaction (PPI) Network, Survival analysis, Spearman Correlation Analysis | STRING (11.0) database and Cytoscape (3.7.2) software, GSCA Lite, Molecular Complex Detection, Centralities for Cytoscape (Centiscape2.2),Gene Ontology,KEGG) pathway enrichment, BloodSpot, Cancer Therapeutics Response Portal (CTRP) analysis,DAVID,Genomics of Drug Sensitivity in Cancer (GDSC) | GSE947626 samples of AML patients and 20 samples of healthy volunteers, while GSE30029 contained 90 samples of AML patients and 31 samples of healthy volunteers | Expression, Methylation |
PPBP | mRNA | Human | Upregulation | Prognostic and Predictive | mRNA chip datasets comparison between AML patients and normal BM tissues | p<0.05 | GEPIA2,TCGA and GEO ,blood | 35116245 | Functional Enrichment Analysis, Protein-Protein Interaction (PPI) Network, Survival analysis, Spearman Correlation Analysis | STRING (11.0) database and Cytoscape (3.7.2) software, GSCA Lite, Molecular Complex Detection, Centralities for Cytoscape (Centiscape2.2),Gene Ontology,KEGG) pathway enrichment, BloodSpot, Cancer Therapeutics Response Portal (CTRP) analysis,DAVID,Genomics of Drug Sensitivity in Cancer (GDSC) | GSE947626 samples of AML patients and 20 samples of healthy volunteers, while GSE30029 contained 90 samples of AML patients and 31 samples of healthy volunteers | Expression, Methylation |
CSF2RB | mRNA | Human | Upregulation | Prognostic and Predictive | mRNA chip datasets comparison between AML patients and normal BM tissues | p<0.05 | GEPIA2,TCGA and GEO ,blood | 35116245 | Functional Enrichment Analysis, Protein-Protein Interaction (PPI) Network, Survival analysis, Spearman Correlation Analysis | STRING (11.0) database and Cytoscape (3.7.2) software, GSCA Lite, Molecular Complex Detection, Centralities for Cytoscape (Centiscape2.2),Gene Ontology,KEGG) pathway enrichment, BloodSpot, Cancer Therapeutics Response Portal (CTRP) analysis,DAVID,Genomics of Drug Sensitivity in Cancer (GDSC) | GSE947626 samples of AML patients and 20 samples of healthy volunteers, while GSE30029 contained 90 samples of AML patients and 31 samples of healthy volunteers | Expression, Methylation |
MRC1 | mRNA | Human | Upregulation | Prognostic and Predictive | mRNA chip datasets comparison between AML patients and normal BM tissues | p<0.05 | GEPIA2,TCGA and GEO ,blood | 35116245 | Functional Enrichment Analysis, Protein-Protein Interaction (PPI) Network, Survival analysis, Spearman Correlation Analysis | STRING (11.0) database and Cytoscape (3.7.2) software, GSCA Lite, Molecular Complex Detection, Centralities for Cytoscape (Centiscape2.2),Gene Ontology,KEGG) pathway enrichment, BloodSpot, Cancer Therapeutics Response Portal (CTRP) analysis,DAVID,Genomics of Drug Sensitivity in Cancer (GDSC) | GSE947626 samples of AML patients and 20 samples of healthy volunteers, while GSE30029 contained 90 samples of AML patients and 31 samples of healthy volunteers | Expression, Methylation |
MAP4K1 | shRNA | Human, mice | Upregulation | Prognostic and Predictive | Moharringtonine (HHT)-resistant and Homoharringtonine (HHT)-sensitive cell line(MV4-11 R10, MV4-11 R30, MV4-11 R50. The MV4-11 (CVCL_0064), MV4-11 R10, MV4-11 R30, MV4-11 R50, MOLM13 (CVCL_2119) and THP-1 (CVCL_0006), KG-1 (CVCL_1824), HL-60 (CVCL_A794), Kasumi (CVCL_058) | p<0.01 | Bone Marrow | 34166980 | RNA-seq profiling, STR profiling, student's t-tests, Multivariate analysis, Kaplan -Mayer method, Log-rank Test, Cox Regression Model | IVIS, GraphPad Prism 5, Calcusyn, GEPIA, DE Seq R package | 178 patients | Expression, Methylation |
CD37 | mRNA | Human | Upregulation | Prognostic | GDM-1, HL-60, KG-1, Kasumi-1, Kasumi-6, ME-1, MOLM-13, MOLM-16, MUTZ-3, OCI-AML3, OCI-AML2,OCI-AML5, OCI-M1 and SIG-M5 | p<0.01 | cBioPortal,CCLE | 32400873 | RNA-seq, Pathway Enrichment Analysis ,Protein–Protein Interaction (PPI) Network Analysis, Differential Expression Analysis, PROFILE Plotting, Correlation Analysis, Patient Survival Analysis, Similar Gene Detection And Dimensionality Reduction Analysis | GEPIA,UALCAN, metascape, DiseaseMeth | 5000 tumor samples from 20 studies | Expression, Methylation |
SHKBP1 | mRNA | Human | Upregulation | Prognostic | GDM-1, HL-60, KG-1, Kasumi-1, Kasumi-6, ME-1, MOLM-13, MOLM-16, MUTZ-3, OCI-AML3, OCI-AML2,OCI-AML5, OCI-M1 and SIG-M6 | p<0.01 | cBioPortal,CCLE | 32400873 | RNA-seq, Pathway Enrichment Analysis ,Protein–Protein Interaction (PPI) Network Analysis, Differential Expression Analysis, PROFILE Plotting, Correlation Analysis, Patient Survival Analysis, Similar Gene Detection And Dimensionality Reduction Analysis | GEPIA,UALCAN, metascape, DiseaseMeth | 5001 tumor samples from 20 studies | Expression, Methylation |
PDLM2 | mRNA | Human | Upregulation | Prognostic | GDM-1, HL-60, KG-1, Kasumi-1, Kasumi-6, ME-1, MOLM-13, MOLM-16, MUTZ-3, OCI-AML3, OCI-AML2,OCI-AML5, OCI-M1 and SIG-M7 | p<0.01 | cBioPortal,CCLE | 32400873 | RNA-seq, Pathway Enrichment Analysis ,Protein–Protein Interaction (PPI) Network Analysis, Differential Expression Analysis, PROFILE Plotting, Correlation Analysis, Patient Survival Analysis, Similar Gene Detection And Dimensionality Reduction Analysis | GEPIA,UALCAN, metascape, DiseaseMeth | 5002 tumor samples from 20 studies | Expression, Methylation |
HMHA1 | mRNA | Human | Upregulation | Prognostic | GDM-1, HL-60, KG-1, Kasumi-1, Kasumi-6, ME-1, MOLM-13, MOLM-16, MUTZ-3, OCI-AML3, OCI-AML2,OCI-AML5, OCI-M1 and SIG-M8 | p<0.01 | cBioPortal,CCLE | 32400873 | RNA-seq, Pathway Enrichment Analysis ,Protein–Protein Interaction (PPI) Network Analysis, Differential Expression Analysis, PROFILE Plotting, Correlation Analysis, Patient Survival Analysis, Similar Gene Detection And Dimensionality Reduction Analysis | GEPIA,UALCAN, metascape, DiseaseMeth | 5003 tumor samples from 20 studies | Expression, Methylation |
RNPEPL1 | mRNA | Human | Upregulation | Prognostic | GDM-1, HL-60, KG-1, Kasumi-1, Kasumi-6, ME-1, MOLM-13, MOLM-16, MUTZ-3, OCI-AML3, OCI-AML2,OCI-AML5, OCI-M1 and SIG-M9 | p<0.01 | cBioPortal,CCLE | 32400873 | RNA-seq, Pathway Enrichment Analysis ,Protein–Protein Interaction (PPI) Network Analysis, Differential Expression Analysis, PROFILE Plotting, Correlation Analysis, Patient Survival Analysis, Similar Gene Detection And Dimensionality Reduction Analysis | GEPIA,UALCAN, metascape, DiseaseMeth | 5004 tumor samples from 20 studies | Expression, Methylation |
CSK | mRNA | Human | Upregulation | Prognostic | GDM-1, HL-60, KG-1, Kasumi-1, Kasumi-6, ME-1, MOLM-13, MOLM-16, MUTZ-3, OCI-AML3, OCI-AML2,OCI-AML5, OCI-M1 and SIG-M10 | p<0.01 | cBioPortal,CCLE | 32400873 | RNA-seq, Pathway Enrichment Analysis ,Protein–Protein Interaction (PPI) Network Analysis, Differential Expression Analysis, PROFILE Plotting, Correlation Analysis, Patient Survival Analysis, Similar Gene Detection And Dimensionality Reduction Analysis | GEPIA,UALCAN, metascape, DiseaseMeth | 5005 tumor samples from 20 studies | Expression, Methylation |
TREX1 | mRNA | Human | Upregulation | Prognostic | GDM-1, HL-60, KG-1, Kasumi-1, Kasumi-6, ME-1, MOLM-13, MOLM-16, MUTZ-3, OCI-AML3, OCI-AML2,OCI-AML5, OCI-M1 and SIG-M11 | p<0.01 | cBioPortal,CCLE | 32400873 | RNA-seq, Pathway Enrichment Analysis ,Protein–Protein Interaction (PPI) Network Analysis, Differential Expression Analysis, PROFILE Plotting, Correlation Analysis, Patient Survival Analysis, Similar Gene Detection And Dimensionality Reduction Analysis | GEPIA,UALCAN, metascape, DiseaseMeth | 5006 tumor samples from 20 studies | Expression, Methylation |
WAS | mRNA | Human | Upregulation | Prognostic | GDM-1, HL-60, KG-1, Kasumi-1, Kasumi-6, ME-1, MOLM-13, MOLM-16, MUTZ-3, OCI-AML3, OCI-AML2,OCI-AML5, OCI-M1 and SIG-M12 | p<0.01 | cBioPortal,CCLE | 32400873 | RNA-seq, Pathway Enrichment Analysis ,Protein–Protein Interaction (PPI) Network Analysis, Differential Expression Analysis, PROFILE Plotting, Correlation Analysis, Patient Survival Analysis, Similar Gene Detection And Dimensionality Reduction Analysis | GEPIA,UALCAN, metascape, DiseaseMeth | 5007 tumor samples from 20 studies | Expression, Methylation |
FST317& FST344 isoforms | mRNA | Zebrafish,human, mice | Upregulation | Predictive | Xenotransplantation of FLT3/ITD mRNA from human to mice & zebrafish | p<0.01 | Serum | 32134197 | Fst targetting by shrna, Crispr/cas9 or Antisense Oligo, Chromatin Immunoprecipitation (CHIP)-qPCR, molecular cloning, lentivirus transfection, RNA-sequencing and proteomics analysis, LC-MS/MS using Orbitrap Fusion Lumos Mass Spectrometer Interfaced With Dionex 3000rslc Nanol ,elisa,apoptosis And Clonogenic Analyses | STAR version 2.5, RSEM version 1.2.31, BSeq version 1.10.0,volcano plot (GraphPad), Gene Ontology Consortium, Partek Genomics Suite, Maxquant version 1.5.3.30, Andromeda algorithm | Wild-type AB zebrafish line, AML cell lines (V4-11, MOLM-13, THP-1, OCI-AML3, KG-1, ML2, NB-4, and Kasumi-1) | Expression, Methylation |
miR-122 | miRNA | Human | Downregulation | Prognostic | lower and higher BM miR-122 expression in de novo AML patients | p<0.05 | Bone marrow | 29627222 | Cox-regression analysis, Mann-Whitney’s U test, Pearson Chi-square analysis/Fisher exact test, Kaplan-Meier method, Univariate and multivariate analysis of Cox regression models | SPSS software (version 20.0) | 116 de novo AML patients including 55 CN-AML patients | Expression, Methylation |
hsa‐miR‐509 | miRNA | Human | Upregulation | Prognostic | AML dataset were divided into training set and testing set | p<0.05 | TCGA | 30242879 | Multivariate and Univariate Cox model, Risk score, Kaplan‐Meier curve, Random permutation test | TargetScan, miRanda, and miRTarBase | 229 patients and 59 CN-AML cohorts | Expression, Methylation |
hsa‐miR‐542 | miRNA | Human | Upregulation | Prognostic | AML dataset were divided into training set and testing set | p<0.05 | TCGA | 30242879 | Multivariate and Univariate Cox model, Risk score, Kaplan‐Meier curve, Random permutation test | TargetScan, miRanda, and miRTarBase | 230 patients and 59 CN-AML cohorts | Expression, Methylation |
hsa‐miR‐146a | miRNA | Human | Upregulation | Prognostic | AML dataset were divided into training set and testing set | p<0.05 | TCGA | 30242879 | Multivariate and Univariate Cox model, Risk score, Kaplan‐Meier curve, Random permutation test | TargetScan, miRanda, and miRTarBase | 231 patients and 59 CN-AML cohorts | Expression, Methylation |
hsa‐miR‐3667 | miRNA | Human | Upregulation | Prognostic | AML dataset were divided into training set and testing set | p<0.05 | TCGA | 30242879 | Multivariate and Univariate Cox model, Risk score, Kaplan‐Meier curve, Random permutation test | TargetScan, miRanda, and miRTarBase | 232 patients and 59 CN-AML cohorts | Expression, Methylation |
miR‑135a | miRNA | Human | Downregulation | Prognostic | HL60, AML193, AML2, AML5 and HS-5 normal cells, AML patient samples and normal samples | p<0.05 | Blood | 29845297 | Kaplan-Meier method, Log-rank test, Two-tail Student's t-test, one-way ANOVA andTukey's post hoc test | NA | 29 AML patients and 11 normal cohorts | Expression, Methylation |
HOXA10 | miRNA | Human | Downregulation | Prognostic | HL60, AML193, AML2, AML5 and HS-5 normal cells, AML patient samples and normal samples | p<0.05 | Blood | 29845297 | Kaplan-Meier method, Log-rank test, Two-tail Student's t-test, one-way ANOVA andTukey's post hoc test | NA | 30 AML patients and 11 normal cohorts | Expression, Methylation |
miR-34a | miRNA | Human | Downregulation | Prognostic | Normal vs diseased | p<0.05 | Serum | 29945348 | Kruskal-Wallis test, Chi- 85 square test, Kaplan- 89 Meier method | GraphPad Prism 6.0 and Statistical Program for 78 Social Sciences 18.0 software | 117 AML patients and 60 normal cohorts, 56 CN-AML patients | Expression, Methylation |
microRNA-328 | miRNA | Human | Downregulation | Prognostic | Normal vs diseased | p<0.05 | Plasma | 26185105 | Mann–Whitney U-test, paired t test, Chi-square analysis ,Fisher exact test, Univariate logistic regression analysis, multivariate logistic analysis, Kaplan-Meier method and log-rank test | SPSS 16.0 | 176 AML patients and 70 healthy cohorts | Expression, Methylation |
miR-3151 | miRNA | Human | Upregulation | Prognostic | Expression of miR-3151 alone vs in combination with BAALC | p<0.05 | Bone marrow | 26430723 | Kaplan–Meier method, log-rank test, Gray test, χ2-test, t-test, Fisher's exact test, Cox proportional hazards model, multivariate analysis | R 2.12 software, MaxStat package, TIGR Multiexperiment viewer version 4.0 software and BRB Array Tools version 3.5.0 software | 181 IR-AML patients | Expression, Methylation |
miR-362-5p | miRNA | Human | Upregulation | Prognostic | High vs low expression of miR-362-5p in AML patients | p<0.05 | Bone marrow | 29540187 | Kaplan–Meier method, univariate analysis, Cox proportional hazard regression model, multivariate analysis, nonparametric test and Chi square test | R software | 224 AML patients | Expression, Methylation |
miR-216b | miRNA | Human | Upregulation | Prognostic and Predictive | Normal vs diseased | p<0.05 | Bone marrow | 28884855 | Mann-Whitney’s U test, Pearson Chi-square analysis/Fisher exact test, Kaplan-Meier analysis and Cox regression analysis (univariate and multivariate analysis). | SPSS software version 20.0 | 115 de novo AML patients and 32 healthy donors | Expression, Methylation |
NPM1 | DNA | Human | Upregulation | Prognostic | Mutations in de novo CN-AML adult | p<0.06 | Bone marrow | 36937459 | Mann-Whitney-U test, Fisher’s exact test, multivariate Cox proportional hazard model | SPSS statistical software package( version 20.0), STATA software (version 11) | 151 CN-AML patients | Expression, Methylation |
CEBPA | DNA | Human | Upregulation | Prognostic | Mutations in de novo CN-AML adult | p<0.07 | Bone marrow | 36937459 | Mann-Whitney-U test, Fisher’s exact test, multivariate Cox proportional hazard model | SPSS statistical software package( version 20.0), STATA software (version 11) | 152 CN-AML patients | Expression, Methylation |